2707 results about "Phospholipid" patented technology

To provide a technique for enhancing the dermal delivery of a composition and, furthermore, enhancing the delivery of the composition to macrophage-surrounding areas.SOLUTION: The present invention provides a liposome with a particle diameter of 300 nm or less, comprising (A) polyglycerin fatty acid ester, (B) phospholipid, and (C) sterol. In a preferred embodiment, the liposome further comprises (D) an amphiphilic molecule having a disaccharide-to-trisaccharide hydrophilic group and an alkyl-chain hydrophobic group within its molecular structure.SELECTED DRAWING: None

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.

The invention provides a preparation method of mitochondria-targeted antioxidant hybrid vesicles. The preparation method comprises the following steps: S1, preparing and separating adipose-derived stem cell nano-vesicles; s2, preparing a liposome loaded with dihydromyricetin and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide by an ethanol injection method; and S3, preparing the hybrid nano vesicles loaded with the dihydromyricetin and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide. The invention also provides the hybrid vesicles prepared by the method and application of the hybrid vesicles in preparation of refractory diabetes wound treatment drugs. The lipidosome and the adipose-derived stem cell nano-vesicles are hybridized to prepare the hybridized vesicles capable of targeting mitochondria and resisting oxidation, the hybridized vesicles are applied to wound treatment for the first time, the problem of oxidative stress of diabetic wounds is solved, wound healing is accelerated, and a new strategy is provided for optimizing mitochondrial function defects and oxidative stress of the diabetic wounds.

The invention belongs to the technical field of microbial fermentation and food engineering, and discloses a fermentation method for enhancing the production capacity of schizochytrium limacinum phospholipid DHA and application, schizochytrium limacinum is subjected to fermentation culture for 32-60 h, and the addition of an organic nitrogen source and phosphate is optimized in the fermentation culture process; the formula of a seed culture medium for culturing schizochytrium limacinum is not changed, and only the formula of a fermentation culture medium for schizochytrium limacinum is changed. The invention provides a fermentation strategy for enhancing the production capacity of the schizochytrium limacinum phospholipid DHA, and the schizochytrium limacinum can obtain the phospholipid DHA with higher content by optimizing an organic nitrogen source and phosphate in a schizochytrium limacinum fermentation culture medium. According to the obtained schizochytrium limacinum grease, the total DHA content is obviously increased compared with that of a traditional fermentation strategy, and the proportion of phospholipid DHA is also remarkably increased. The regulation and control method is applied to preparation of schizochytrium limacinum algae powder, the schizochytrium limacinum algae powder rich in phospholipid DHA is obtained, and application of the schizochytrium limacinum algae powder in the field of aquatic feed is facilitated.

The invention relates to a universal nano biological vesicle preparation method. The preparation method comprises the following steps: carrying out crude extraction on cells from bacteria, fungi, plants or animals to obtain a crude extracting solution; the crude extracting solution is placed in a low-temperature and high-pressure homogenizer to be subjected to low-temperature and high-pressure homogenizing treatment, then the nano vesicles are obtained, the low-temperature and high-pressure homogenizer comprises a high-pressure cavity, a homogenizing valve, a working cavity, a conveying system and a temperature control system, a slit is formed in the homogenizing valve, and the crude extracting solution located in the high-pressure cavity enters the working cavity through the slit of the homogenizing valve, the pressure intensity of the high-pressure cavity is 300-3000 bar, and the working temperature of the high-pressure homogenizer is 0-10 DEG C. The activation energy is reduced by controlling high-pressure and low-temperature environments, so that the original cell membrane structure is broken, the cell wall structure is destroyed, and phospholipid bimolecules are driven to aggregate and self-assemble to form the vesicles. For biological membranes derived from bacteria, fungi, plants and animals, the vesicles can be prepared by the preparation method disclosed by the invention, and the method has universality.

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel cationic lipid as well as additional lipids such as ionizable lipids, phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and / or prophylactic agents such as RNA are useful in the delivery of therapeutic and / or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The invention discloses a liver-targeting drug liposome and application thereof, and relates to the field of drug delivery, cholate and mannose are used for respectively modifying phospholipid molecules DSPE-PEG2000, two raw materials DSPE-PEG2000-CA and DSPE-PEG2000-MAN composed of the liposome are synthesized, and then the liposome is prepared into the liver-targeting drug liposome. The liposome with liver targeting property is obtained from the liposome, cholesterol, DSPC, DC-cholesterol and a water-soluble therapeutic drug according to a certain proportion, the liposome has relatively high cell safety and liver targeting property, and the therapeutic effect of the corresponding drug can be remarkably improved after the drug is embedded.

The invention belongs to the technical field of medicine, and discloses an active targeting atherosclerotic plaque liposome and application thereof in diagnosis, a carrier material for forming the liposome comprises targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polypropylene sulfide-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the targeting peptide R8 modified methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), the polypropylene sulfide-polyethylene glycol (PPS-PEG) and the cholesterol (CH) are combined to form the active targeting atherosclerotic plaque liposome. The sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg, and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Gln-Cys-His- The liposome provided by the invention can improve the enrichment concentration of a fluorescent dye or a drug in local lesion, and has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on diagnosis of atherosclerosis.

The invention provides a liposome preparation and a preparation method thereof, the liposome preparation comprises an ion pairing agent, phospholipid or a derivative thereof, sterol, a lipid molecule derivative and a drug compound, the ion pairing agent comprises at least one of a compound (I) and a compound (II), and the compound (II) comprises at least one of a compound (III) and a compound (III). Structures in the compound (I) and the compound (II) contain a plurality of functional groups (such as amide, carbonyl, thioether and the like), so that abundant binding sites are provided for drug molecules, and the compound (I) and the compound (II) can interact with different types of drug compounds (such as fat-soluble and water-soluble drugs); the liposome preparation is allowed to be combined with various drug molecules through hydrogen bonds, hydrophobic interaction or electrostatic interaction, and the liposome preparation adapts to physicochemical properties of different drugs. The compound (I) and the compound (II) further comprise different hydrophobic groups (such as alkyl chains) and hydrophilic groups (such as sulfonic acid, carboxylic acid and the like), so that the liposome preparation has the amphiphilic characteristic, not only can encapsulate hydrophobic drugs, but also can encapsulate hydrophilic drugs, and the variety and range of encapsulated drugs are improved.

The invention relates to a multi-effect bionic liposome transdermal repair carrier and a preparation method and application thereof.The multi-effect bionic liposome transdermal repair carrier comprises active ingredients and a nano-carrier, and the active ingredients comprise sialic acid, saccharomycetes / rice fermentation product filtrate, arginine / lysine polypeptide and vitamin E in the mass ratio of (1-10): (2-8): (0.1-1): (0.5-4); the nano-carrier is prepared from the following raw materials: phospholipid, an emulsifier, polyhydric alcohol and water. Compared with the prior art, the anti-aging, whitening and moisturizing composition has the advantages of enhancing skin moisturizing and anti-oxidation effects, promoting collagen synthesis and inhibiting tyrosinase to achieve remarkable anti-aging, whitening and moisturizing effects and the like.

The invention discloses glycerin entrapped with recombinant human collagen III and a preparation method and application thereof, and belongs to the technical field of medicines and cosmetics, the glycerin entrapped with recombinant human collagen III comprises phospholipid, glycerin, Tween 80, chitosan quaternary ammonium salt, sodium hyaluronate, recombinant human collagen III and a PBS buffer solution. Glycerin which has high deformation performance and can effectively penetrate through the stratum corneum is prepared, and double-layer modification of chitosan quaternary ammonium salt and sodium hyaluronate is carried out on the glycerol to deliver the recombinant human-derived III-type collagen, so that the problems that the recombinant human-derived III-type collagen is high in hydrophilicity, large in molecular weight and difficult to penetrate through the stratum corneum of the skin can be effectively solved; the bioavailability and the percutaneous penetration of the recombinant human III type collagen are obviously improved.

The invention relates to the field of cosmetics, and relates to a collagen-containing cosmetic, in particular to application of a reverse micelle carrier in preparation of a cosmetic for improving collagen intradermal retention volume. The cosmetic comprises a collagen composite raw material, the collagen composite raw material comprises the following components in percentage by mass: 53.55-80% of grease; 15 to 60 percent of phospholipid; 0.5 to 1.5 percent of an antioxidant; 0.1 to 2 percent of water; and 0.01% to 0.5% of collagen; the grease is prepared from any one of isopropyl myristate, isopropyl laurate or isopropyl acetate; the phospholipid comprises lecithin, and the purity of the lecithin is 90% or above. The retention amount of the collagen in the cosmetic containing the collagen in the skin can be increased, so that the collagen permeates into the skin epidermis or dermis and accumulates in the skin layer; the real collagen supplementing effect of cosmetics is greatly improved, and the skin young state is facilitated.

The invention discloses a uric acid reducing apigenin cyclodextrin inclusion compound liposome and a preparation method thereof. The uric acid reducing apigenin cyclodextrin inclusion compound liposome is prepared from the following components in parts by weight: 1 part of apigenin, 2 to 50 parts of beta-cyclodextrin, 0.8 to 30 parts of phospholipid and 0.1 to 10 parts of surfactant. According to the invention, apigenin is included in beta-cyclodextrin to obtain the apigenin cyclodextrin inclusion compound, and the water solubility of apigenin can be improved and the molecular volume can be increased through a cyclodextrin inclusion method to reduce the ability of apigenin to penetrate through a phospholipid bilayer; and the apigenin cyclodextrin inclusion compound is encapsulated in the liposome to obtain the apigenin cyclodextrin inclusion compound liposome, so that the stability of the liposome is fundamentally improved, and the problem of liposome drug leakage in a liquid state is solved. The whole water solubility of the apigenin cyclodextrin inclusion compound liposome provided by the invention is improved, the apigenin cyclodextrin inclusion compound liposome has good stability and slow release effect, the bioavailability of apigenin is improved, and the uric acid reducing effect is obviously superior to that of untreated apigenin.

The invention provides a therapeutic drug monitoring kit and method and system, a magnetic bead extraction method is combined with LC-MS / MS detection to be applied to human blood drug concentration monitoring, a mixed magnetic bead solution containing phospholipid removal magnetic beads and to-be-detected drug adsorption magnetic beads is utilized to perform adsorption and extraction pretreatment on a to-be-detected drug in a sample, automatic treatment equipment is matched, and the concentration of the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug is detected. The pretreatment efficiency is high, the phospholipid content in the supernate is low, and the matrix effect and the chromatographic column washing pressure are greatly reduced. According to the therapeutic drug monitoring method provided by the invention, a unified pretreatment process is used, simultaneous extraction of multiple drugs is realized, and through a magnetic bead automatic extraction method, the pretreatment step of a sample can be rapidly completed, a therapeutic drug monitoring result can be rapidly obtained, the overall detection time is shortened, and the detection efficiency is improved. Therefore, a reliable laboratory examination basis is provided for individualized treatment.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

Disclosed in the present invention is a method for simultaneously preparing high-purity sphingomyelin and glycerol phosphocholine. The method comprises the following steps: 1) adding a degradation agent to a phospholipid mixture to degrade phospholipid, so as to obtain a sphingomyelin and glycerol phosphocholine mixture, and carrying out separation by means of a refining method to obtain a crude product; 2) carrying out column chromatography to obtain sphingomyelin having a purity higher than 98%; and 3) obtaining glycerol phosphocholine having a purity higher than 95% by means of a refining method; and 4) drying same to obtain a phospholipid satisfying the pharmaceutical standard. The solvent used in the present invention can be recycled and reused and is environmentally friendly, and the method has mild reaction conditions, good selectivity, low requirement for the raw material purity, and a relatively low production cost, and is beneficial to industrial mass production.

The invention discloses a brain-targeted active oxygen responsive hydrogen sulfide donor liposome, a preparation method and an application, and belongs to the technical field of pharmaceutical preparations, the structure of the brain-targeted active oxygen responsive hydrogen sulfide donor liposome comprises a lipid material and a hydrogen sulfide donor encapsulated in the lipid material, the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid, and the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid. The active oxygen sensitive lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and an active oxygen sensitive bond, and the brain-targeted lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and brain-targeted peptide. The hydrogen sulfide donor lipidosome can penetrate through a blood brain barrier, target neuronal cells, respond to an active oxygen environment of a focus part and sensitively release a hydrogen sulfide donor, so that hydrogen sulfide is distributed in the focus neuronal cells, active oxygen and active nitrogen substances are effectively removed, oxidation and nitration stress are inhibited, and damage and death of the neuronal cells are reduced; the growth and functional recovery of neuronal cells are promoted, and the application prospect in the aspect of treating central nervous system injury diseases is good.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-di oxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

The invention discloses an antibody-modified lipid nanoparticle, a preparation method thereof and application of the antibody-modified lipid nanoparticle as a targeting carrier. The invention provides lipid nanoparticles coupled with an antibody and loaded with nucleic acid. The lipid nanoparticles are characterized in that raw materials of the lipid nanoparticles consist of ionizable lipid, phospholipid, steroidal lipid, PEG lipid and PEG-Mal lipid, the PEG lipid is C16-PEG2k, and the PEG-Mal lipid is C16-PEG2k-Mal, and the PEG-Mal lipid is C16-PEG2k-Mal. The method aims at the key scientific problems of low delivery efficiency, insufficient targeting and the like in the field of in-vivo hematopoietic stem / progenitor cell gene therapy at present. The invention develops a lipid nanoparticle delivery system based on antibody modification, provides a modular antibody targeted delivery platform with high universality, and shows huge clinical transformation potential.

The invention provides an inhalable tanshinone IIA lipid nanocrystal as well as a preparation method and application thereof, and the inhalable tanshinone IIA lipid nanocrystal is mainly formed by entrapping tanshinone IIA by using dipalmitoyl phosphatidylcholine DPPC and dipalmitoyl phosphatidyl ethanolamine DPPE as mixed phospholipids in the presence of a stabilizer. Compared with the prior art, the inhalable tanshinone IIA lipid nanocrystal disclosed by the invention has the advantages that by improving the physicochemical property and drug release behavior of TA, the lung retention volume of TA after aerosol inhalation is obviously increased, the retention time of TA in the lung is prolonged, and the risk of toxic and side effects caused by whole-body escape of drugs is reduced; the treatment effect on idiopathic pulmonary fibrosis is improved, and the compliance of a patient is improved.

The invention provides an enzyme response type supramolecular PDRN-mini ECM liposome and a preparation method and application thereof.The enzyme response type supramolecular PDRN-mini ECM liposome comprises phospholipid, a membrane stabilizer, a supramolecular compound and an emulsifier, a water phase formed by the supramolecular compound and the emulsifier serves as an inner core, and the supramolecular compound is formed by PDRN and mini ECM through intermolecular acting force; the mini ECM is formed by self-assembly of collagen peptide, elastin and hyaluronic acid. The supramolecular PDRN-mini ECM liposome with uniform particle size and good stability is obtained through a microfluidic technology, the process is simple, the controllability is high, and amplification is easy.

The present invention relates to an oxygen-carrying nanoliposome in which oxygen is carried inside a shell of a phospholipid bilayer, and use thereof. The nanoliposome continuously releases oxygen, thereby maintaining an oxygen delivery effect for a long time, and increases anticancer efficacy without damaging the cells by delivering oxygen specifically to tumor cells.

The invention discloses antioxidant salmon collagen peptide and a preparation method thereof, and belongs to the technical field of processing of salmon collagen peptide. The preparation method comprises the following steps: firstly, carrying out enzymolysis on the salmon material by using phospholipase A2, hydrolyzing abundant membrane phospholipids in the salmon material, destroying fat cell structures and releasing wrapped triglyceride, then carrying out secondary enzymolysis by using aspergillus oryzae lipase, hydrolyzing macromolecular lipids into free fatty acids which are easily dissolved in supercritical carbon dioxide, and carrying out secondary enzymolysis by using aspergillus oryzae lipase. The degreased salmon material is obtained by means of supercritical carbon dioxide extraction, the lipid removal rate is greatly increased, and the antioxidant salmon collagen peptide which is small in molecular weight and high in oxidation resistance is obtained through subsequent collagen extraction and enzymolysis.

Targeting liposomes for protein degrader delivery. In one embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader. In other embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader- ligase complex. Also provided are kits for preparing targeting liposomes for protein degrader and / or protein degrader-ligase complexes. Also provided are methods for preparing such targeting liposomes.

The invention relates to nucleic acid medicine eye drops and a preparation method thereof. The nucleic acid drug eye drops comprise nucleic acid drug-loaded lipid nanoparticles and cell-penetrating peptides modified on the surfaces of the lipid nanoparticles, the lipid nanoparticle comprises a core and a surface layer, and the core comprises ionizable lipid and a phospholipid layer which are coated on the surface of the nucleic acid drug; the surface layer comprises ionizable lipid, phospholipid, cholesterol and modified polylysine; the modified polylysine is grafted with the cell-penetrating peptide. The nucleic acid drug eye drops have high stability, can realize noninvasive delivery of nucleic acid drugs, and complete treatment of posterior segment diseases of eyes.

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

The invention provides schizochytrium limacinum FJ-1 and application thereof in production of phospholipid type EPA (eicosapentaenoic acid). The application comprises the following steps: taking a cryopreserved schizochytrium limacinum strain, and inoculating the schizochytrium limacinum strain into a liquid seed culture medium for pre-culture; the method comprises the following steps: inoculating pre-cultured schizochytrium limacinum into a fermentation tank according to the inoculum size of 5-10% v / v, culturing for 48-60 hours at the sea salt concentration of 0.5-1% w / v, fermenting for 48-72 hours, supplementing sea salt to a culture medium in batches until the sea salt concentration is 3-5% w / v, and continuously culturing for 96-120 hours by controlling the glucose concentration and the yeast extract concentration through supplementing materials. The technical problem that the synthesis efficiency of schizochytrium limacinum phospholipid type EPA is low is solved through precise regulation and control of salinity stress, an efficient, economical and generalizable innovative scheme is provided for industrial production of functional lipid, and the method is suitable for large-scale production.